Aurinia Pharmaceuticals Stock Fair Value – Aurinia Pharmaceuticals Stock Soars 8% as Q4 Net Loss Narrows and Revenue Grows Year-Over-Year.
March 1, 2023
Trending News 🌧️
Aurinia Pharmaceuticals Stock Fair Value – The positive news sent investors into a buying spree, pushing Aurinia Pharmaceuticals ($NASDAQ:AUPH)’ stock price up 8%. The company’s Q4 net loss was -$26.05M, a significant decrease from the -$33.86M reported in the same quarter last year.
Company officials hope that the revenue growth and narrowing of their Q4 net loss shows that their new strategy is already bearing fruit. Investors seem to agree and are showing confidence in the company’s future prospects with the 8% jump in their stock price.
Share Price
On Tuesday, Aurinia Pharmaceuticals stock opened at $8.2, closing at $9.1, with the stock rising by 9.1% from the prior closing price of 8.3. This impressive growth was largely due to their Q4 net loss narrowing and revenue growing year-over-year. Although the media coverage of Aurinia Pharmaceuticals has mostly been negative, the stock soared 8% in response to their improving financial performance. It appears investors remain optimistic about the company’s future prospects, despite the lack of positive news. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 134.03 | -108.18 | -80.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -79.53 | -60.63 | 2.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 470.86 | 65.42 | 2.98 |
Key Ratios Snapshot
Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 649.8% | – | -83.2% |
| FCF Margin | ROE | ROA |
| -59.6% | -16.8% | -14.8% |
Analysis – Aurinia Pharmaceuticals Stock Fair Value
At GoodWhale, we believe it is important to stay up-to-date on the financials of AURINIA PHARMACEUTICALS. By analyzing AURINIA PHARMACEUTICALS’s financials with our analysis tools, we found that their intrinsic value per share is approximately $720.2. This is calculated using our proprietary Valuation Line. Currently, AURINIA PHARMACEUTICALS’s stock is trading at only $9.1, making it deeply undervalued by 98.7%. To take advantage of this significant opportunity, you may want to consider investing in AURINIA PHARMACEUTICALS. More…
Peers
The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.
– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)
Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.
– Vaxart Inc ($NASDAQ:VXRT)
Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.
– MediWound Ltd ($NASDAQ:MDWD)
MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
Summary
Aurinia Pharmaceuticals has seen its stock price move up 8% despite recent negative media exposure. The company reported a narrowed net loss and year-over-year revenue growth in its Q4 earnings report. In terms of investing analysis, the results suggest the potential for a positive future outlook. Investors should consider Aurinia Pharmaceuticals as a stock that is likely to provide good returns, particularly in the long-term.
As the company continues to grow, investors can expect further gains as well as potential dividends. Overall, Aurinia Pharmaceuticals remains a sound investing choice.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
